Zynerba's stock on a high as cannabis-based drug succeeds in trial

(Reuters) - Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel met the main goal in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities in adolescents and children.